FROM THE ARCHIVE
Acne drug to get suicide warning
Facebook
Twitter
Email
DECEMBER 6, 2000 The Food and Drug Administration on Tuesday said patients who use a popular, powerful, and highly effective acne drug called Accutane will receive a brochure warning them of its possible, but unproven, link to suicide. The move comes after consumer concern about the product. The 17-year-old son of Rep. Bart Stupak (D-Mi) committed suicide in May and his parents link it to his use of the drug. The FDA is also developing stricter rules on the use and prescription of the drug. The House Committee on Government Reform held a hearing on the drug yesterday. Get the Story:
FDA: New consumer warnings on Accutane, including possible suicide risk (AP 12/5) Relevant Links:
Accutane, Rep. Bart Stupak - www.house.gov/stupak/accutane.htm
Accutane Info - www.capederm.com/info_accutane.htm
Accutane, Yahoo! Health - health.yahoo.com/health/Drugs_Tree/Medication_or_Drug/0216
The House Committee on Government Reform - www.house.gov/reform
Advertisement
Stay Connected
Contact
Search
Trending in News
1 White House Council on Native American Affairs meets quick demise under Donald Trump
2 'A process of reconnecting': Young Lakota actor finds ways to stay tied to tribal culture
3 Jenni Monet: Bureau of Indian Affairs officer on leave after fatal shooting of Brandon Laducer
4 'A disgraceful insult': Joe Biden campaign calls out Navajo leader for Republican speech
5 Kaiser Health News: Sisters from Navajo Nation died after helping coronavirus patients
2 'A process of reconnecting': Young Lakota actor finds ways to stay tied to tribal culture
3 Jenni Monet: Bureau of Indian Affairs officer on leave after fatal shooting of Brandon Laducer
4 'A disgraceful insult': Joe Biden campaign calls out Navajo leader for Republican speech
5 Kaiser Health News: Sisters from Navajo Nation died after helping coronavirus patients
News Archive
About This Page
You are enjoying stories from the Indianz.Com Archive, a collection dating back to 2000. Some outgoing links may no longer work due to age.
All stories are available for publishing via Creative Commons License: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)